ALUMIS INC.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Martin Babler and John Schroer his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 19, 2025, by the following persons on behalf of the registrant and in the capacities indicated:
| | | |
|---|---|---|
| Signature | | Title |
| | | |
| /s/ Martin Babler | | President and Chief Executive Officer and Director |
| Martin Babler | | (Principal Executive Officer) |
| | | |
| /s/ John Schroer | | Chief Financial Officer |
| John Schroer | | (Principal Financial and Accounting Officer) |
| | | |
| /s/ Srinivas Akkaraju, M.D., Ph.D. | | Director |
| Srinivas Akkaraju, M.D., Ph.D. | | |
| | | |
| /s/ Alan B. Colowick, M.D., M.P.H. | | Director |
| Alan B. Colowick M.D., M.P.H. | | |
| | | |
| /s/ Patrick Machado | | Director |
| Patrick Machado, J.D. | | |
| | | |
| /s/ Sapna Srivastava, Ph.D. | | Director |
| Sapna Srivastava, Ph.D. | | |
| | | |
| /s/ James B. Tananbaum, M.D. | | Director |
| James B. Tananbaum, M.D. | | |
| | | |
| /s/ Zhengbin Yao, Ph.D. | | Director |
| Zhenbgin Yao, Ph.D. | | |
| | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.